![MIPS Seminar - Shan X. Wang, PhD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/shan-wang_profilephoto-300x300.jpg)
MIPS Seminar Series: “Circulating Tumor DNA Biomarkers for Therapy Monitoring and Early Detection”
Shan X. Wang, PhD
Leland T. Edwards Professor in the School of Engineering
Professor of Materials Science & Engineering, jointly of Electrical Engineering, and by courtesy of Radiology (Stanford School of Medicine)
Director, Stanford Center for Magnetic Nanotechnology
Stanford University
Location: Zoom
Webinar URL: https://stanford.zoom.us/s/93202777468
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 932 0277 7468
Passcode: 851144
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
Inspired by Dr Sam Gambhir, MIPS, Canary Center, and Stanford CCNE have pursued in vivo imaging and in vitro diagnostic tests for cancer therapeutic response or early detection, respectively, over the last 15+ years. Here I present two successful examples based on circulating tumor DNA (ctDNA) targets in plasma, complementary to imaging modalities such as CT and Ultrasound.
We have developed a simple yet highly sensitive assay for the detection of actionable mutational targets such as Epidermal Growth Factor Receptor (EGFR) and Kirsten rat sarcoma oncogene (KRAS) mutations in the plasma ctDNA from non-small cell lung cancer (NSCLC) patients using giant magnetoresistive (GMR) nanosensors. Our assay achieves lower limits of detection compared to standard fluorescent PCR based assays, and comparable performance to digital PCR methods. In 30 patients with metastatic disease and known EGFR mutation status at diagnosis, our assay achieved 87.5% sensitivity for Exon19 deletion and 90% sensitivity for L858R mutation while retaining 100% specificity; additionally, our assay detected secondary T790M mutation resistance with 96.3% specificity while retaining 100% sensitivity. We re-sampled 13 patients undergoing tyrosine kinase inhibitor (TKI) therapy 2 weeks after initiation to assess response, our GMR assay was 100% accurate in correlation with longitudinal clinical outcome, and the responders identified by the GMR assay had significantly improved progression free survival (PFS) compared to the non-responders. The GMR assay is low cost, rapid, and portable, making it ideal for detecting actionable mutations at diagnosis and non-invasively monitoring treatment response in the clinic.
On another front, we have also developed a highly sensitive and multiplexed assay for the detection of methylated ctDNA targets in plasma samples. Current diagnostic tests for liver cancer in at-risk patients are cumbersome, costly and inaccurate, resulting in a need for accurate blood-based tests. By devising a Layered Analysis of Methylated Biomarkers (LAMB) from the relevant big data, we have discovered a set of DNA targets in the blood that accurately detects liver cancer in these at-risk patients. This set of methylated targets was found by analyzing the genetic information of 3411 liver cancer patients and 1722 healthy people. Our results could lead to clinical adoption of liquid biopsy tests for liver cancer surveillance in high-risk populations and the development of blood tests for other cancers.
ABOUT
Prof. Wang directs the Center for Magnetic Nanotechnology and is a leading expert in biosensors, information storage and spintronics. His research and inventions span across a variety of areas including magnetic biochips, in vitro diagnostics, cancer biomarkers, magnetic nanoparticles, magnetic sensors, magnetoresistive random access memory, and magnetic integrated inductors. He has over 300 publications, and holds 65 issued or pending patents in these and interdisciplinary areas. He was named an inaugural Fred Terman Fellow, and was elected a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a Fellow of American Physical Society (APS) for his seminal contributions to magnetic materials and nanosensors. His team won the Grand Challenge Exploration Award from Gates Foundation (2010), the XCHALLENGE Distinguished Award (2014), and the Bold Epic Innovator Award from the XPRIZE Foundation (2017).
Dr. Wang cofounded three high-tech startups in Silicon Valley, including MagArray, Inc. and Flux Biosciences, Inc. In 2018 MagArray launched a first of its kind lung cancer early diagnostic assay based on protein cancer biomarkers and support vector machine (SVM). In 2019, Flux Biosciences launched a human trial to offer at-home testing of fertility based on hormones and magneto-nanosensors. Through his participation in the Center for Cancer Nanotechnology Excellence (as co-PI of the CCNE) and the Joint University Microelectronics Program (JUMP), he is actively engaged in the transformative research of healthcare and is developing emerging memories for energy efficient computing.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![MIPS Seminar - Jennifer Dionne, PhD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/jennifer-dionne_profilephoto-300x300.jpg)
MIPS Seminar Series: Emerging nanophotonic platforms for infectious disease diagnostics: Re-imagining the conventional microbiology toolkit
Jennifer Dionne, PhD
Senior Associate Vice Provost for Research Platforms/Shared Facilities
Associate Professor of Material Science and Engineering and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Stanford University
Location: Zoom
Webinar URL: https://stanford.zoom.us/j/95883654314
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 958 8365 4314
Passcode: 105586
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
We present our research controlling light at the nanoscale for infectious disease diagnostics, including detecting bacteria at low concentration, sensing COVID gene sequences, and visualizing in-vivo inter-cellular forces. First, we combine Raman spectroscopy and deep learning to accurately classify bacteria by both species and antibiotic resistance in a single step. We design a convolutional neural network (CNN) for spectral data and train it to identify 30 of the most common bacterial strains from single-cell Raman spectra, achieving antibiotic treatment identification accuracies exceeding 99% and species identification accuracies similar to leading mass spectrometry identification techniques. Our combined Raman-CNN system represents a proof-of-concept for rapid, culture-free identification of bacterial isolates and antibiotic resistance. Second, we describe resonant nanophotonic surfaces, known as “metasurfaces” that enable multiplexed detection of SARS-CoV-2 gene sequences. Our metasurfaces utilize guided mode resonances excited in high refractive index nanostructures. The high quality factor modes produce a large amplification of the electromagnetic field near the nanostructures that increase the response to targeted binding of nucleic acids; simultaneously, the optical signal is beam-steered for multiplexed detection. We describe how this platform can be manufactured at scale for portable, low-cost assays. Finally, we introduce a new class of in vivo optical probes to monitor biological forces with high spatial resolution. Our design is based on upconverting nanoparticles that, when excited in the near-infrared, emit light of a different color and intensity in response to nano-to-microNewton forces. The nanoparticles are sub-30nm in size, do not bleach or photoblink, and can enable deep tissue imaging with minimal tissue autofluorescence. We present the design, synthesis, and characterization of these nanoparticles both in vitro and in vivo, focusing on the forces generated by the roundworm C. elegans as it feeds and digests its bacterial food.
ABOUT
Jennifer Dionne is the Senior Associate Vice Provost of Research Platforms/Shared Facilities and an associate professor of Materials Science and Engineering and, by courtesy, of Radiology at Stanford. She is also an Associate Editor of Nano Letters, director of the DOE-funded Photonics at Thermodynamic Limits Energy Frontier Research Center, and an affiliate faculty of the Wu Tsai Neurosciences Institute, the Institute for Immunity, Transplantation, and Infection, and Bio-X. Jen received her B.S. degrees in Physics and Systems Science and Mathematics from Washington University in St. Louis, her Ph. D. in Applied Physics at the California Institute of Technology in 2009, and her postdoctoral training in Chemistry at Berkeley. Her research develops nanophotonic methods to observe and control chemical and biological processes as they unfold with nanometer scale resolution, emphasizing critical challenges in global health and sustainability. Her work has been recognized with the Alan T. Waterman Award, a NIH Director’s New Innovator Award, a Moore Inventor Fellowship, the Materials Research Society Young Investigator Award, and the Presidential Early Career Award for Scientists and Engineers, and was featured on Oprah’s list of “50 Things that will make you say ‘Wow’!”. Beyond the lab, Jen enjoys exploring the intersection of art and science, long-distance cycling, and reliving her childhood with her two young sons.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![MIPS Special Seminar - Jubilant Biosys @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/Headshots-for-Calendar.jpg)
MIPS Special Seminar: Jubilant Biosys: Drug discovery and contract research services, from target discovery to candidate selection
Thomas Haywood, PhD
Head of International Radiochemistry Collaborations
Stanford University
Saurabh Kapure, MBA
Vice President, Business Development (USA & APAC)
Jubilant Biosys Limited
Jay Sheth, MBA
Manager Business Development, Drug Discovery Services, and CDMO
Jubilant Biosys Limited
LOCATION: Zoom
Meeting URL: https://stanford.zoom.us/j/98108346345
Dial: +1 650 724 9799 or +1 833 302 1536
Meeting ID: 981 0834 6345
Passcode: 397741
9:00-9:15 AM, PT – Thomas Haywood – Stanford Radiology projects
9:40-10:00 AM, PT – Moderated by Jason Thanh Lee – Discussion
ABOUT
Jubilant Biosys, an integrated contract research organization in India with business offices in Asia and North America, is a leading collaborator for biotechnology and pharmaceutical companies, with in-depth expertise in discovery informatics, medicinal chemistry, structural biology, and in vitro pharmacology services. Jubilant Biosys provides comprehensive drug discovery services and contract research services, from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared). This seminar will showcase case studies from recent Stanford projects and a discussion of future opportunities.
Sponsored by: Molecular Imaging Program at Stanford, Department of Radiology
![MIPS Seminar - Geoffrey Sonn, MD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/geoffrey-sonn_profilephoto-300x300.jpg)
MIPS Seminar Series: Image-guided focal therapy for prostate cancer
Geoffrey Sonn, MD
Assistant Professor of Urology and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Stanford University Medical Center
Location: Zoom
Webinar URL: https://stanford.zoom.us/s/96126703618
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 961 2670 3618
Passcode: 186059
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
In recent years, prostate cancer treatment has increasingly focused on selecting patients who are most likely to benefit and reducing harms from treatment. This has been seen both in adoption of active surveillance for men with low-risk prostate cancer and emergence of image-guided focal ablative therapy. While focal therapy causes fewer sexual and urinary side effects than conventional prostate cancer treatments, many questions remain about proper patient selection, treatment planning, and follow up care.
Improvements in prostate MRI performance and interpretation have paved the way for adoption of focal therapy. However, clinical challenges remain in prostate cancer imaging. This talk will describe prostate cancer focal therapy, discuss patient selection, and highlight the research efforts of my group to improve MRI interpretation to guide biopsy and improve focal therapy performance.
ABOUT
Geoffrey Sonn, MD is a urologic oncologist who specializes in treating patients with prostate and kidney cancer. He has a particular interest in cancer imaging, MRI-Ultrasound fusion targeted prostate biopsy, prostate cancer focal therapy, and robotic surgery for prostate and kidney cancer. He is the principal investigator of the first clinical trial in Northern California to use MRI-guided focused ultrasound to treat prostate cancer. The goal of this trial is to treat prostate cancer with fewer side effects than surgery or radiation.
Dr. Sonn was born in Washington State and lived there until leaving for college at Georgetown. After graduating magna cum laude at Georgetown he returned to the West Coast for medical school at UCLA. Following medical school, Dr. Sonn completed a 6-year urology residency at Stanford where he developed particular interests in the clinical care of patients with urologic cancers and research in cancer imaging. Dr. Sonn completed a 2-year urologic oncology fellowship at UCLA. Since completing his fellowship, Dr. Sonn has been at Stanford as an assistant professor in urology. Dr. Sonn’s research is devoted to developing new cancer imaging techniques, applying artificial intelligence to find cancers on medical images, and applying new methods to treat prostate cancer with fewer side effects.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![MIPS Seminar - David K. Stevenson, MD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/david-stevenson_profilephoto-300x300.jpg)
MIPS Seminar Series: Predicting and Preventing Fetal and Neonatal Pathology: Looking Back and Looking Forward
David K. Stevenson, MD
The Harold K. Faber Professor of Pediatrics, Senior Associate Dean, Maternal and Child Health and Professor, by courtesy, of Obstetrics and Gynecology
Lucile Packard Children’s Hospital
Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/94584828060
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 945 8482 8060
Passcode: 481874
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
The importance of minimally invasive technologies for interrogating the fetus and newborn, as well as of knowing where a biologic system is headed, not just where it has been, when trying to predict and prevent acquired diseases, will be discussed. Examples of such technologies, such as trace gas analysis and optical reporting of biologic phenomena, and their application to model systems and the human newborn will be presented. The role of advanced computational approaches for the integration and interpretation of large amounts of data derived from these new measurement tools will be emphasized.
ABOUT
Dr. David K. Stevenson is the Harold K. Faber Professor of Pediatrics and has made many impactful contributions to the field of neonatology and pediatrics, including his seminal studies on neonatal jaundice, bilirubin production and heme oxygenase biology. As a neonatologist, his research has focused primarily on neonatal jaundice and more recently on the causes of preterm birth and its prevention. He has held numerous leadership roles at Stanford University School of Medicine, including Vice Dean and Senior Associate Dean for Academic Affairs. He is currently the Senior Associate Dean for Maternal & Child Health, the Co-Director of the Stanford Maternal & Child Health Research Institute, and the Principal Investigator for the March of Dimes Prematurity Research Center at Stanford University. Dr. Stevenson has received many awards, including the Virginia Apgar Award, which is the highest award in Perinatal Pediatrics, the Joseph W. St. Geme, Jr. Leadership Award from the Federation of Pediatric Organizations, the Jonas Salk Award for Leadership in Prematurity Prevention from the March of Dimes Foundation, and the John Howland Medal and Award, the highest award in academic pediatrics. He has served as the President of the American Pediatric Society. In recognition of his achievements, Dr. Stevenson is a member of the National Academy of Medicine.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![MIPS Seminar - Steven Paul Poplack, MD @ Venue coming soon!](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/steven-poplack-300x300.jpg)
MIPS Seminar Series: Title TBA
Steven Paul Poplack, MD
Professor of Radiology (Breast Imaging)
Stanford University Medical Center
Location: Coming soon!
12:00pm – 12:45pm Seminar & Discussion
RSVP: Coming soon!
ABSTRACT
Coming soon!
ABOUT
Coming soon!
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![MIPS Seminar - Matthew Bogyo, PhD @ Venue coming soon!](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/BogyoHeadshotJuly2017-244x300.jpg)
MIPS Seminar Series: Title TBA
Matthew Bogyo, PhD
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology
Stanford University
Location: Coming soon!
12:00pm – 12:45pm Seminar & Discussion
RSVP: Coming soon!
ABSTRACT
Coming soon!
ABOUT
Dr. Bogyo received a B.Sc. degree in Chemistry from Bates College in 1993 and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology in 1997. After completion of his degree he was appointed as a Faculty Fellow in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Bogyo served as the Head of Chemical Proteomics at Celera Genomics from 2001 to 2003 while maintaining an Adjunct Faculty appointment at UCSF. In the Summer of 2003 Dr. Bogyo joined the Department of Pathology at Stanford Medical School and was appointed as a faculty member in the Department of Microbiology and Immunology in 2004. His interests are focused on the use of chemistry to study the role of proteases in human disease. In particular his laboratory is currently working on understanding the role of cysteine proteases in tumorgenesis and also in the life cycle of human parasites and bacterial pathogens. Dr. Bogyo currently serves on the Editorial Board of Biochemical Journal, Cell Chemical Biology, Molecular and Cellular Proteomics and is an Academic Editor at PLoS One. Dr. Bogyo is a consultant for several biotechnology and pharmaceutical companies in the Bay Area and is a founder and board member of Akrotome Imaging and Facile Therapeutics.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
Roxana Daneshjou, MD, PhD
Assistant Professor, Biomedical Data Science & Dermatology
Assistant Director, Center of Excellence for Precision Heath & Pharmacogenomics
Director of Informatics, Stanford Skin Innovation and Interventional Research Group
Stanford University
Title: Building Fair and Trustworthy AI for Healthcare
Abstract: AI for healthcare has the potential to revolutionize how we practice medicine. However, to do this in a fair and trustworthy manner requires special attention to how AI models work and their potential biases. In this talk, I will cover the considerations for building AI systems that improve healthcare.
Mildred Cho, PhD
Professor of Pediatrics, Center of Biomedical Ethics
Professor of Medicine, Primary Care and Population Health
Stanford University
Title: Facilitating Patient and Clinician Value Considerations into AI for Precision Medicine
Abstract:
For the development of ethical machine learning (ML) for precision medicine, it is essential to understand how values play into the decision-making process of developers. We conducted five group design exercises with four developer participants each (N=20) who were asked to discuss and record their design considerations in a series of three hypothetical scenarios involving the design of a tool to predict progression to diabetes. In each group, the scenario was first presented as a research project, then as development of a clinical tool for a health care system, and finally as development of a clinical tool for their own health care system. Throughout, developers documented their process considerations using a virtual collaborative whiteboard platform. Our results suggest that developers more often considered client or user perspectives after changing the context of the scenario from research to a tool for a large healthcare setting. Furthermore, developers were more likely to express concerns arising from the patient perspective and societal and ethical issues such as protection of privacy after imagining themselves as patients in the health care system. Qualitative and quantitative data analysis also revealed that developers made reflective/reflexive statements more often in the third round of the design activity (44 times) than in the first (2) or second (6) rounds. These statements included statements on how the activity connected to their real-life work, what they could take away from the exercises and integrate into actual practice, and commentary on being patients within a health care system using AI. These findings suggest that ML developers can be encouraged to link the consequences of their actions to design choices by encouraging “empathy work” that directs them to take perspectives of specific stakeholder groups. This research could inform the creation of educational resources and exercises for developers to better align daily practices with stakeholder values and ethical ML design.
Ifeoma Okoye MBBS, FWACS, FMCR
Professor of Radiology and Director
University of Nigeria Centre for Clinical Trials
College of Medicine, University of Nigeria
Title: Deepening Collaboration with Stanford & Pennsylvania, Toward Developing Joint Strategies to Close the ‘Cancer Care’ & ‘Clinical Trial Volume’ Gap in LMICs
Abstract
In this seminar I will be addressing the dire cancer survival outcomes in low- and middle-income countries (LMICs), with a particular focus on Sub-Saharan Africa. Cancer survival rates in Sub-Saharan Africa are alarmingly low. According to the World Health Organization, cancer deaths in LMICs account for approximately 70% of global cancer fatalities. In Nigeria, the five-year survival rate for breast cancer, one of the most common cancers, stands at a disheartening 10-30%, compared to over 80% in high-income countries. This stark disparity highlights the urgent need for sustained comprehensive cancer interventions in our region.
Here, I will discuss the pivotal role in the cancer control sphere, of a new software, ONCOSEEK, capable of early detecting 11 types of Cancers! It’s particular emphasis on the Patient Perspective, which aligns with our ethos of need for holistic patient care. In addition I will discuss recent developments on collaborative effort with the Gevaert lab at Stanford University and the University of Pennsylvania.